Boston-Bio-Tissue Inc. introduced a new procedure for conjunctivochalasis-the reservoir restoration procedure for conjunctivochalasis (CCH) dry eye.
The procedure restores the tear reservoir and tear meniscus to their natural states using cryopreserved amniotic membrane and inhibits matrix metalloproteinases activity. While there are currently different techniques for CCH, none currently address the Tenon’s capsule, which new evidence suggests will lead to more successful and durable outcomes, according to the company.
This new surgical procedure offers two techniques that remove the unhealthy Tenon, one using sutures, and the other without.
“Our new [procedure] uses cryopreserved amniotic membrane to help reduce inflammation, promote regenerative healing, suppress pain, and achieve superior cosmetic results,” said Tom Daniells, chief commercial officer, Bio-Tissue. “For patients with CCH dry eye, this is extremely beneficial as it helps to speed recovery and provides a solution for those patients who don’t respond well to medical treatment.”
For more articles in this issue of Ophthalmology Times’ Conference Brief, click here.
